Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 153 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Follow-Up Questions
Molecular Partners AG 的 CEO 是誰？
Dr. Patrick Amstutz 是 Molecular Partners AG 的 Chief Executive Officer，自 2006 加入公司。
MOLN 股票的價格表現如何？
MOLN 的當前價格為 $3.78，在上個交易日 decreased 了 3.51%。
Molecular Partners AG 的主要業務主題或行業是什麼？
Molecular Partners AG 屬於 Biotechnology 行業，該板塊是 Health Care
